Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation

Authors: Jeffrey J. Heard, Ivy Phung, Mark I. Potes, Fuyuhiko Tamanoi

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

RHEB is a unique member of the RAS superfamily of small GTPases expressed in all tissues and conserved from yeast to humans. Early studies on RHEB indicated a possible RHEB-RAF interaction, but this has not been fully explored. Recent work on cancer genome databases has revealed a reoccurring mutation in RHEB at the Tyr35 position, and a recent study points to the oncogenic potential of this mutant that involves activation of RAF/MEK/ERK signaling. These developments prompted us to reassess the significance of RHEB effect on RAF, and to compare mutant and wild type RHEB.

Methods

To study RHEB-RAF interaction, and the effect of the Y35N mutation on this interaction, we used transfection, immunoprecipitation, and Western blotting techniques. We generated cell lines stably expressing RHEB WT, RHEB Y35N, and KRAS G12V, and monitored cellular transforming properties through cell proliferation, anchorage independent growth, cell cycle analysis, and foci formation assays.

Results

We observe a strong interaction between RHEB and BRAF, but not with CRAF. This interaction is dependent on an intact RHEB effector domain and RHEB-GTP loading status. RHEB overexpression decreases RAF activation of the RAF/MEK/ERK pathway and RHEB knockdown results in an increase in RAF/MEK/ERK activation. RHEB Y35N mutation has decreased interaction with BRAF, and RHEB Y35N cells exhibit greater BRAF/CRAF heterodimerization resulting in increased RAF/MEK/ERK signaling. This leads to cancer transformation of RHEB Y35N stably expressing cell lines, similar to KRAS G12 V expressing cell lines.

Conclusions

RHEB interaction with BRAF is crucial for inhibiting RAF/MEK/ERK signaling. The RHEB Y35N mutant sustains RAF/MEK/ERK signaling due to a decreased interaction with BRAF, leading to increased BRAF/CRAF heterodimerization. RHEB Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB and BRAF resulting in overactive RAF/MEK/ERK signaling. Taken together with the previously established function of RHEB to activate mTORC1 signaling, it appears that RHEB performs a dual function; one is to suppress the RAF/MEK/ERK signaling and the other is to activate mTORC1 signaling.

Available only for authorised users

Aspuria P-J, Tamanoi F. The Rheb family of GTP-binding proteins. Cell Signal. 2004;16(10):1105–12.CrossRefPubMed

Yamagata K, Sanders LK, Kaufmannn WE, Yee W, Barnes CA, Nathans D, Paul WF. Rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J Biol Chem. 1994;269(23):16333–9.PubMed

Gromov PS, Madsen P, Tomerup N, Celis JE. A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rheb. FEBS Lett. 1995;377(2):221–6.CrossRefPubMed

Clark JC, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is Farnesylated and antagonizes Ras signaling and transformation. J Biol Chem. 1997;272(16):10608–15.CrossRefPubMed

N. Mizuki, M. Kimura, S. Ohno, S. Miyata, M. Sato, H. Ando, M. Ishihara, K. Goto, S. Watanabe, M. Yamazaki, A. Ono, S. Taguchi, K. Okumura, M. Nogami, H. Taguchi, A. Ando, and H. Inoko, “Isolation of cDNA and genomic clones of a human Ras-related GTP-binding protein gene and its chromosomal localization to the long arm of chromosome 7, 7q36,” 1996.

Patel PH, Thapar N, Guo L, Martinez M, Maris J, Gau C-L, Lengyel JA, Tamanoi F. Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J Cell Sci. 2003;116(17):3601–10.CrossRefPubMed

Heard JJ, Fong V, Bathaie SZ, Tamanoi F. Recent progress in the study of the Rheb family GTPases. Cell Signal. 2014;26(9):1950–7.CrossRefPubMedPubMedCentral

Yu Y, Li S, Xu X, Li Y, Guan K, Arnold E, Ding J. Structural basis for the unique biological function of small GTPase RHEB. J Biol Chem. 2005;280(17):17093–100.CrossRefPubMed

Mazhab-Jafari MT, Marshall CB, Ishiyama N, Ho J, Di Palma V, Stambolic V, Ikura M. An autoinhibited noncanonical mechanism of GTP hydrolysis by Rheb maintains mTORC1 homeostasis. Structure. 2012;20(9):1528–39.CrossRefPubMed

10.

Marshall CB, Ho J, Buerger C, Plevin MJ, Li G-Y, Li Z, Ikura M, Stambolic V. Characterization of the intrinsic and TSC2-GAP-regulated GTPase activity of Rheb by real-time NMR. Sci Signal. 2009;2(55):ra3.CrossRefPubMed

11.

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501.CrossRefPubMedPubMedCentral

12.

Wang Y, Hong X, Wang J, Yin Y, Zhang Y, Zhou Y, Piao H, Liang Z, Zhang L, Li G, Xu G, Kwiatkowski DJ, Liu Y. Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth. Oncogene. 2017;36(6):756–65.CrossRefPubMed

13.

Yee WM, Worley PF. Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol Cell Biol. 1997;17(2):921–33.CrossRefPubMedPubMedCentral

14.

Im E, von Lintig FC, Chen J, Zhuang S, Qui W, Chowdhury S, Worley PF, Boss GR, Pilz RB. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene. 2002;21(41):6356–65.CrossRefPubMed

15.

Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem. 2006;281(35):25447–56.CrossRefPubMed

16.

Neuman NA, Henske EP. Non-canonical functions of the tuberous sclerosis complex-Rheb signaling axis. EMBO Mol Med. 2011;3:189–200.

17.

Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol. 2003;5(6):566–71.CrossRefPubMed

18.

Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem. 2009;284(19):12783–91.CrossRefPubMedPubMedCentral

19.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93.CrossRefPubMedPubMedCentral

20.

Beggs AD, Latchford AR, Vasen HFA, Moslein G, Alonso A, Aretz S. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975–86.

21.

Inoki K, Guan K-L. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet. 2009;18(1):94–100.CrossRef

22.

Henske EP, McCormack FX, McCormack F, Kinder B, Seyama K, Nishimura M, Kwiatkowski D. Lymphangioleiomyomatosis - a wolf in sheep’s clothing. J Clin Invest. 2012;122(11):3807–16.CrossRefPubMedPubMedCentral

23.

Patel M, Côté J-F. Ras GTPases’ interaction with effector domains: breaking the families’ barrier. Commun Integr Biol. 2013;6(4):e24298-1–9.CrossRef

24.

Malumbres M, Barbacid M. Timeline: RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459–65.CrossRefPubMed

25.

Lacher MD, Pincheira R, Zhu Z, Camoretti-Mercado B, Matli M, Warren RS, Castro AF. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene. 2010;29(50):6543–56.CrossRefPubMed

26.

Sun Y, Fang Y, Yoon M-S, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, Brown HA, Chen J. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A. 2008;105(24):8286–91.CrossRefPubMedPubMedCentral

27.

Lee MN, Ha SH, Kim J, Koh A, Lee CS, Kim JH, Jeon H, Kim D-H, Suh P-G, Ryu SH. Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Mol Cell Biol. 2009;29(14):3991–4001.CrossRefPubMedPubMedCentral

28.

Shahani N, Pryor W, Swarnkar S, Kholodilov N, Thinakaran G, Burke RE, Subramaniam S. Rheb GTPase regulates β-secretase levels and amyloid β generation. J Biol Chem. 2014;289(9):5799–808.CrossRefPubMed

29.

Kim HW, Ha SH, Lee MN, Huston E, Kim D-H, Jang SK, Suh P-G, Houslay MD, Ryu SH. Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D. Mol Cell Biol. 2010;30(22):5406–20.CrossRefPubMedPubMedCentral

30.

Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S. Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. J Biol Chem. 2015;290(2):1096–105.CrossRefPubMed

31.

Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F. Significance of filamin a in mTORC2 function in glioblastoma. Mol Cancer. 2015;14(1):127.CrossRefPubMedPubMedCentral

32.

Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem. 2004;279(29):29930–7.CrossRefPubMed

33.

Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005;15(8):702–13.CrossRefPubMed

34.

Tabancay AP, Gau C-L, Machado IMP, Uhlmann EJ, Gutmann DH, Guo L, Tamanoi F. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem. 2003;278(41):39921–30.CrossRefPubMed

35.

Weber CK, Slupsky JR, Kalmes HA, Rapp UR. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 2001;61:3595–8.PubMed

36.

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Project CG, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by Oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.CrossRefPubMed

37.

L. K. Rushworth, A. D. Hindley, E. O’Neill, and W. Kolch, “Regulation and role of Raf-1/B-Raf heterodimerization.,” Mol Cell Biol, vol. 26, no. 6, pp. 2262–2272, 2006.

38.

Weinberg RA. Use of Transfection to analyze genetic information and malignant transformation. Biochim Biophys Acta. 1981;651:25–35.PubMed

39.

Clark GJ, Cox AD, Graham SM, Der CJ. Biological assays for Ras transformation. Methods Enzymol. 1995;255:395–412.CrossRefPubMed

40.

Fischer A, Hekman M, Kuhlmann J, Rubio I, Wiese S, Rapp UR. B- and C-RAF display essential differences in their binding to Ras. J Biol Chem. 2007;282(36):26503–16.CrossRefPubMed

Title: An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation
Authors: Jeffrey J. Heard
Ivy Phung
Mark I. Potes
Fuyuhiko Tamanoi
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3938-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Staining of E-selectin ligands on paraffin-embedded sections of tumor tissue

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

High postoperative monocyte indicates inferior Clinicopathological characteristics and worse prognosis in lung adenocarcinoma or squamous cell carcinoma after lobectomy

Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy

Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy

Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer